Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients

Cancers

Valeria Grazia Malagnino¹  Francesca Mazzoni²  Chiara Moroni³  Vittorio Miele³  Diletta Cozzi³  Salvatore Cappabianca⁴  Riccardo Monti⁴  Giorgia Viola La Casella⁴  Carmine Picone⁵  Antonella Petrillo⁵  Vincenza Granata⁵  Roberta Grassi⁶  Roberto Grassi⁶  Roberta Fusco⁷  Matilde Costa⁸  Agnese Montanino⁹ 

[1] Dipartimento Diagnosi e Terapia per Immagini, Radiologia Diagnostica, IRCCS Istituto Tumori G, Paolo II, I-70124 Bari, Italy;Division of Oncology, Azienda Ospedaliero-Universitaria Careggi, I-50134 Firenze, Italy;Division of Radiodiagnostic, Azienda Ospedaliero-Universitaria Careggi, I-50134 Firenze, Italy;Division of Radiodiagnostic, Università degli Studi della Campania Luigi Vanvitelli, I-80128 Naples, Italy;Division of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, I-80131 Naples, Italy;Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, I-20122 Milan, Italy;Medical Oncology Division, Igea SpA, I-80013 Naples, Italy;R & D Lab. of Tecnologie Avanzate TA Srl, Science and Technology Park, I-10153 Udine, Italy;Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, I-80131 Naples, Italy;

关键词: lung adenocarcinoma;    radiomics;    computed tomography;    texture analysis;    morphological analysis;   

DOI  :  10.3390/cancers13163992

来源: DOAJ

【 摘 要 】

Purpose: To assess the efficacy of radiomics features obtained by computed tomography (CT) examination as biomarkers in order to select patients with lung adenocarcinoma who would benefit from immunotherapy. Methods: Seventy-four patients (median age 63 years, range 42–86 years) with histologically confirmed lung cancer who underwent immunotherapy as first- or second-line therapy and who had baseline CT studies were enrolled in this approved retrospective study. As a control group, we selected 50 patients (median age 66 years, range 36–86 years) from 2005 to 2013 with histologically confirmed lung adenocarcinoma who underwent chemotherapy alone or in combination with targeted therapy. A total of 573 radiomic metrics were extracted: 14 features based on Hounsfield unit values specific for lung CT images; 66 first-order profile features based on intensity values; 43 second-order profile features based on lesion shape; 393 third-order profile features; and 57 features with higher-order profiles. Univariate and multivariate statistical analysis with pattern recognition approaches and the least absolute shrinkage and selection operator (LASSO) method were used to assess the capability of extracted radiomics features to predict overall survival (OS) and progression free survival (PFS) time. Results: A total of 38 patients (median age 61; range 41–78 years) with confirmed lung adenocarcinoma and subjected to immunotherapy satisfied inclusion criteria, and 50 patients in a control group were included in the analysis The shift in the center of mass of the lesion due to image intensity was significant both to predict OS in patients subjected to immunotherapy and to predict PFS in patients subjected to immunotherapy and in patients in the control group. With univariate analysis, low diagnostic accuracy was reached to stratify patients based on OS and PFS time. Regarding multivariate analysis, considering the robust (two morphological features, three textural features and three higher-order statistical metrics) application of the LASSO approach and all patients, a support vector machine reached the best results for stratifying patients based on OS (area under curve (AUC) of 0.89 and accuracy of 81.6%). Alternatively, considering the robust predictors (six textural features and one higher-order statistical metric) and application of the LASSO approach including all patients, a decision tree reached the best results for stratifying patients based on PFS time (AUC of 0.96 and accuracy of 94.7%). Conclusions: Specific radiomic features could be used to select patients with lung adenocarcinoma who would benefit from immunotherapy because a subset of imaging radiomic features useful to predict OS or PFS time were different between the control group and the immunotherapy group.

【 授权许可】

Unknown